Loading
A phase 1/2 trial of Amivantamab, Pembrolizumab and Carboplatin in head and neck squamous cell carcinoma, run by Janssen Research & Development, LLC, now recruiting.
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer is a phase 1/2 interventional study registered as NCT06385080 by Janssen Research & Development, LLC, with 287 participants planned, started 2024-04-22 and due to reach its primary completion in 2032-12-27. Interventions recorded: Amivantamab, Pembrolizumab, Paclitaxel and Carboplatin.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Carboplatin and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Carboplatin and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Carboplatin and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Carboplatin and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Carboplatin and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/